Skip to Content
Merck
CN

SML2186

Poloppin

≥98% (HPLC)

Synonym(s):

5-(4-Bromophenyl)-1-[2-(trifluoromethyl)phenyl]-1H-pyrrole-2-propanoic acid, Polo protein-protein interaction inhibitor

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C20H15BrF3NO2
CAS Number:
Molecular Weight:
438.24
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C20H15BrF3NO2/c21-14-7-5-13(6-8-14)17-11-9-15(10-12-19(26)27)25(17)18-4-2-1-3-16(18)20(22,23)24/h1-9,11H,10,12H2,(H,26,27)

InChI key

OCUKOJUZSNFVFQ-UHFFFAOYSA-N

SMILES string

OC(CCC1=CC=C(C2=CC=C(Br)C=C2)N1C3=CC=CC=C3C(F)(F)F)=O

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Biochem/physiol Actions

Poloppin is a cell penetrant and potent inhibitor of mitotic Polo-like kinases (PLKs) that binds to the Polo-box domain (PBD) and prevents PLKs interaction with pSer/pThr phosphopeptide substrates. Poloppin induces mitotic arrest and apoptosis in cancer cells expressing mutant KRAS in 2D and organoid cultures. It also sensitizes mutant KRAS-expressing cancer cells to Crizotinib.
cell penetrant and potent inhibitor of PLKs that binds to the Polo-box domain (PBD) and prevents PLKs interaction with phosphopeptide substrates

Storage Class

11 - Combustible Solids

wgk

WGK 3


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ana J Narvaez et al.
Cell chemical biology, 24(8), 1017-1028 (2017-08-16)
Mutations activating KRAS underlie many forms of cancer, but are refractory to therapeutic targeting. Here, we develop Poloppin, an inhibitor of protein-protein interactions via the Polo-box domain (PBD) of the mitotic Polo-like kinases (PLKs), in monotherapeutic and combination strategies to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service